Education
About Us
Working with TipRanks
Follow Us
Oncology Pharma (ONPH)
OTHER OTC:ONPH
Total Valuation
Oncology Pharma has a market cap or net worth of $109.55K. The enterprise value is ―.
Market Cap$109.55K
Enterprise Value―
Share Statistics
Oncology Pharma has 27,388,216 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding27,388,216
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Oncology Pharma’s return on equity (ROE) is -83.90 and return on invested capital (ROIC) is -3.24%.
Return on Equity (ROE)-83.90
Return on Assets (ROA)-49.29
Return on Invested Capital (ROIC)-3.24%
Return on Capital Employed (ROCE)-0.05
Revenue Per Employee―
Profits Per Employee-10.00T>
Employee Count―
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Oncology Pharma is ―. Oncology Pharma’s PEG ratio is 0.02.
PE Ratio―
PS Ratio0.00
PB Ratio90.64
Price to Fair Value90.64
Price to FCF306.66
Price to Operating Cash Flow0.02
PEG Ratio0.02
Income Statement
In the last 12 months, Oncology Pharma had revenue of 0.00 and earned -104.63M in profits. Earnings per share was -3.42.
Revenue0.00
Gross Profit0.00
Operating Income-62.05K
Pretax Income-104.63M
Net Income-104.63M
EBITDA228.68K
Earnings Per Share (EPS)-3.42
Cash Flow
In the last 12 months, operating cash flow was 15.23K and capital expenditures 0.00, giving a free cash flow of 15.23K billion.
Operating Cash Flow15.23K
Free Cash Flow15.23K
Free Cash Flow per Share<0.01
Dividends & Yields
Oncology Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-64.71
52-Week Price Change0.00%
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)―
Important Dates
Oncology Pharma upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Oncology Pharma as a current ratio of <0.01, with Debt / Equity ratio of 53.09%
Current Ratio<0.01
Quick Ratio<0.01
Debt to Market Cap<0.01
Net Debt to EBITDA-83.53
Interest Coverage Ratio>-0.01
Taxes
In the past 12 months, Oncology Pharma has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate<0.01
Enterprise Valuation
Oncology Pharma EV to EBITDA ratio is -14.43K, with an EV/FCF ratio of 308.45.
EV to Sales0.00
EV to EBITDA-14.43K
EV to Free Cash Flow308.45
EV to Operating Cash Flow308.45
Balance Sheet
Oncology Pharma has $398.00 in cash and marketable securities with $777.62K in debt, giving a net cash position of -$777.22K billion.
Cash & Marketable Securities$398.00
Total Debt$777.62K
Net Cash-$777.22K
Net Cash Per Share-$0.03
Tangible Book Value Per Share$0.04
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Oncology Pharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―